Member Info for cf456

The First Equity note is well worth reading and highlights the significant potential upside in MKA from the current price.

"Our investment thesis for Mkango, which we set out in more detail below, is simple: it is the most attractively valued pre-production stage, ex-China REE project on all public markets."

"A crucial element of the agreement between Mkango and Talaxis is the option clause. This stipulates that upon completion of the BFS, Talaxis has the option of increasing its stake in Songwe Hill from 49% to 75% by securing all project finance (estimated at $216m in the PFS – or £168m at current exchange rates). Were Talaxis to fund this capex entirely in the form of equity, that would take its total investment in Songwe Hill to £180m. Based on this transaction, that would value Songwe Hill at £240m – and Mkango’s 25% remaining equity stake at £60m, or 53.1p per share using the current issued share capital of 112.9m."

"At its current share price of 9.95p, Mkango is valued at only £11.2m. We consider this to be brutally undervalued, in light of the size, quality and strategic importance (both from a commercial and a political sense) of Songwe Hill, and of the valuation attributed to it by the Talaxis deal."

https://gallery.mailchimp.com/d266f47cec87da1170bcd0f35/files/5bf0e4f5-88e8-428a-841e-63d25ffd8bf2/Top_10_Micro_Cap_Picks_Part_I.01.pdf

"£5m of this was received in January 2018, which gave Talaxis an initial 20% stake. The remaining £7m is due to be paid in Q1 2019."

https://gallery.mailchimp.com/d266f47cec87da1170bcd0f35/files/5bf0e4f5-88e8-428a-841e-63d25ffd8bf2/Top_10_Micro_Cap_Picks_Part_I.01.pdf

https://cube.investments/infrastrata-infa-gas-powering-my-portfolio/

Agreed.

The person who bought 61745 @ 46p this morning must think so too.

http://goo.gl/qwjFn3

lol.

No doubt they will revise upwards as the year progresses and the deals begin to land.

https://www.finncap.com/news-events/finncap-research-company-notes-21-january-2019

Avacta Group trading in line in "year of very significant progress"

http://goo.gl/Rd3qmp

From the other BB...

---

finnCap today reiterate 120p target...

"Avacta (AVCT): Corp

AGM business update – preclinical progress on 2 fronts

The company has confirmed that H1 FY 2019 is trading in line with market forecasts, and updates relating to its lead bispecific PD-L1/LAG3 Affimer, TMAC Affimer drug conjugate platform and its collaboration with Moderna are encouraging, providing further evidence of the incremental value being created in its Affimer-driven technology platforms.

Management is confident that there will be multiple reagent licensing deals in 2019, given the pipeline of late-stage interest from potential parties. Equally, we would hope/expect further therapeutic licences during 2019, given the preclinical progress that is being made, and building on the LG Chem development deal in December, which has a biodollar value of up to $300m plus royalties.

We reiterate a target price of 120p."

Plenty to look forward to. 2019 going to be a very big year for the company by the sounds of it.

---

"I look forward to updating the market on progress during 2019 which I expect to be a year of very significant progress for the Company."

https://investegate.co.uk/avacta-group-plc--avct-/rns/agm-business-update-and-notice-of-results/201901210700045586N/

"The partnership with LG Chem...is a major milestone for the Company. This deal, potentially worth over $300m and with a significant upfront payment..."

"As we expand those data-sets across our in-house programmes I am very confident that we will see additional significant licensing deals that transform the Company."

"The research collaboration with leading scientists at Tufts University Medical School...is an exciting prospect that has got numerous large pharmaceutical partners interested in the Affimer TMAC(TM) programme."

"The licensing deal with New England Biolabs is a perfect example of the type of deals we have in the pipeline of Affimer reagent evaluations and I expect that we will see more of these deals emerge in 2019 with both large and small partners across multiple markets."

"I look forward to updating the market on progress during 2019 which I expect to be a year of very significant progress for the Company."

https://www.investegate.co.uk/avacta-group-plc--avct-/rns/agm-business-update-and-notice-of-results/201901210700045586N/

https://investegate.co.uk/infrastrata-plc--infa-/rns/exercise-of-warrants-and-change-to-tvr/201901181644235564N/

https://gallery.mailchimp.com/d266f47cec87da1170bcd0f35/files/5bf0e4f5-88e8-428a-841e-63d25ffd8bf2/Top_10_Micro_Cap_Picks_Part_I.01.pdf

The share price can certainly move very quickly when it gets going:

"we would point out that the share price rally in the first two months of 2018 that saw the shares move from under 10p to as high as 35p was almost exclusively driven by announcements relating to positive progress being made with Nuvec. Moreover, subsequent progress with Nuvec has been hugely positive."

Worth watching closely for the next leg up.

First Equity - Top 10 Micro-Cap Picks for 2019

"We believe that the shares are currently materially undervalued, with the wider market having failed to appreciate the potential value of Nuvec."

"We are of the opinion that the current share price offers an incredibly attractive entry into a biotechnology that has genuine potential to make a real impact on the rapidly growing vaccines and therapeutics space."

https://gallery.mailchimp.com/d266f47cec87da1170bcd0f35/files/5bf0e4f5-88e8-428a-841e-63d25ffd8bf2/Top_10_Micro_Cap_Picks_Part_I.01.pdf

http://goo.gl/mucMKV

A dip presenting itself today for a pullback entry opportunity.

The last RNS provided a liquidity event which allowed the likes of Aviva to reduce their position and the other instis to buy.

The next positive RNS and it'll be a lot more difficult to buy a decent position since the recent insitutional purchases have tied up the loose stock.

And of course it's not just a single positive RNS expected. There should be several of them over the coming months.

I can see the price being chased a lot higher as the news starts to flow in earnest.

Pullbacks like the one today offer the chance of getting in on the cheap before those inevitable strong upswings.

Latest presentation from October full of useful info and worth a read:

"Considerable uplift opportunity

Significant milestones should be achieved in the near future that would support considerable valuation uplift and bring Avacta inline with comparators."

https://tinyurl.com/ybl6sybj

A firm price today despite the small sells.

Instis mopping up in the background perhaps whilst small PIs sell. I know which side I'd rather be on.

A little profit taking to be expected I suppose with so many traders in the market these days. But they're missing out on a very much bigger opportunity here imo.

The company is at an inflection point. It's hugely undervalued compared to comparitors and with multiple catalysts in the weeks and months ahead, I expect the share price to move very much higher over time.

There's a strong few years in this imo Ramptastico.

Potential highlighed here:

https://www.youtube.com/watch?v=zS3RF7xV1_c&t=980s (from 16:20)